BIOMARIN PHARMACEUTICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 76.95 USD | -4.29% |
|
-5.84% | -20.19% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 2.74B | Sales 2025 * | 3.09B | Capitalization | 15.27B |
|---|---|---|---|---|---|
| Net income 2024 * | 363M | Net income 2025 * | 504M | EV / Sales 2024 * | 5.32 x |
| Net cash position 2024 * | 698M | Net cash position 2025 * | 1.34B | EV / Sales 2025 * | 4.51 x |
| P/E ratio 2024 * |
42
x | P/E ratio 2025 * |
29.7
x | Employees | 3,401 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.16% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioMarin Pharmaceutical Inc.
More recommendations
More press releases
More news
| 1 day | -4.29% | ||
| 1 week | -5.96% | ||
| Current month | -4.72% | ||
| 1 month | -15.91% | ||
| 3 months | -12.85% | ||
| 6 months | -11.61% | ||
| Current year | -20.19% |
1 week
76.52
81.95
1 month
76.5293.02
Current year
76.5299.25
1 year
76.0299.56
3 years
70.73117.77
5 years
62.88131.95
10 years
55.36151.75
| Managers | Title | Age | Since |
|---|---|---|---|
Alexander Hardy
CEO | Chief Executive Officer | 56 | Nov. 30 |
Brian Mueller
DFI | Director of Finance/CFO | 50 | 02-11-30 |
Kevin Eggan
CTO | Chief Tech/Sci/R&D Officer | - | 20-10-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 16-01-03 |
| Director/Board Member | 70 | 05-05-15 | |
Randy Meier
CHM | Chairman | 65 | 06-12-13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.45% | 1 M€ | +0.15% | - | |
| 1.79% | 0 M€ | 0.00% | - | |
| 1.59% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 76.97 | -4.27% | 3,858,058 |
| 24-05-15 | 80.4 | +0.94% | 2,124,282 |
| 24-05-14 | 79.65 | -1.06% | 1,530,829 |
| 24-05-13 | 80.5 | -0.65% | 1,291,756 |
| 24-05-10 | 81.03 | -0.84% | 1,521,244 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotes
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
Pharmaceuticals
Calendar
2024-05-21
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
80.4
USD
Average target price
109.3
USD
Spread / Average Target
+35.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.19% | 15.27B | |
| +0.10% | 91.42B | |
| +3.16% | 41.08B | |
| -11.10% | 34.26B | |
| +53.99% | 25.27B | |
| -9.41% | 12.81B | |
| -12.25% | 11.6B | |
| -44.00% | 11.42B | |
| +5.77% | 9.16B | |
| -6.90% | 8.22B |
- Stock Market
- Equities
- BMRN Stock
